Tilray's Rescheduling Rally Keeps Fading -- Where Will the Stock Be if Washington Stalls Again?

Tilray shares collapsed from about $23.20 late last year to under $5 near the 52-week low of $3.67, despite U.S. medical-cannabis rescheduling (Schedule I/II to Schedule III). In Q4 FY2026, revenue rose 25% YoY to $281.7M largely from a $53.7M BrewDog asset acquisition, while underlying beverage revenue fell 17% YoY; adjusted optics remain weak with net loss per share at -$0.43 (improved vs -$13.01 largely due to prior impairment charges). Even with potential hearings on broader (adult-use) rescheduling, the article argues risks and structural limits to growth keep the stock unattractive.

Analysis

The market is correctly treating TLRY’s U.S. regulatory optionality as a sentiment trade, not an earnings bridge. Even in a friendlier federal regime, the company’s value capture is constrained by the absence of interstate commerce and by the fact that the real economic prize from rescheduling accrues first to U.S.-centric operators that can translate lower tax drag into immediate EBITDA uplift; TLRY’s Canadian footprint is still a commoditized, price-competitive basin with limited pricing power.

The bigger second-order issue is capital allocation. Management has been using adjacent beverage assets to mask cannabis underperformance, but that segment has lower strategic synergy and risks becoming a distraction if it diverts capital from balance-sheet repair or forces further dilution to fund growth. Over the next 1-3 months, headline risk is asymmetric: any stalled hearing or softened political support can unwind the recent multiple support quickly, while a true policy win likely lifts the whole cannabis basket before TLRY’s fundamentals improve.

Consensus may be underestimating how little rescheduling alone changes TLRY’s competitive position. The structural winners are names with direct U.S. operating leverage or ancillary picks-and-shovels exposure; TLRY remains a late-cycle catch-up story with poor operating momentum. What would falsify the bearish view is evidence that the company can produce durable positive free cash flow from non-cannabis assets without equity dilution, or a policy path that explicitly legalizes interstate distribution and adult-use commerce rather than merely reducing legal risk.

Key Decisions for Investors

• Avoid initiating long TLRY on rescheduling headlines; use any 10-15% pop as a fade candidate over a 1-3 month horizon unless there is a concrete earnings inflection.
• Pair trade: short TLRY / long MSOS for 1-3 months to express the view that U.S.-centric operators capture the first-order economic benefit from policy easing while TLRY remains a low-quality beta name.
• If forced to trade the event, use TLRY call spreads instead of outright calls only into a regulatory catalyst, with a hard stop if the stock fails to hold post-headline gains for 2-3 sessions.
• Watch for equity dilution, debt refinancing, or asset-sale announcements over the next 6-12 months; any capital raise would strengthen the short case and likely compress the multiple further.